Shanghai Laisi (002252.SZ): SR604 Injection New Indications Obtained Drug Clinical Trial Approval.

Tencent Finance App News, Shanghai Hengrui (002252.SZ) announced that the company recently received the "Drug Clinical Trial Approval Letter" issued by the National Medical Products Administration (referred to as "NMPA") on the approval of SR604 injection for the prevention and treatment of bleeding episodes in patients with hemophilia.